PRQR
ProQR Therapeutics NV
NASDAQ · Healthcare · Biotechnology · NL
$1.31
+0.00%Margins
Gross margin
92.3%
EBITDA margin
-203.0%
EBIT margin
-232.7%
Net margin
-228.3%
FCF margin
-270.8%
-53.4%
Return on equity
-31.8%
Return on assets
-46.7%
Return on invested capital
0.15x
Asset turnover
-$55.1M
Cash from operations
$0.93
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026